Biogen, Eisai Win CHMP Backing of Leqembi Alzheimer's Drug
A key European regulatory panel has reversed course and is now recommending approval of Leqembi, the Alzheimer's drug from Biogen and Eisai. The companies on Thursday said the European Medicines ...
Merck Signs up to $3.3 Billion Cancer Drug Deal With China-Based LaNova
(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...